RAD51 and cancer: Indeed, although BRCA1Mut at BRCT domain has been described as associated with chemosensitivity, the breast HCC1937 cancer cells displayed resistance to PARPi related to residual HR activity by retaining the integrity of RAD51 binding region [80].